AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3090987
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (5‐fluorouracil, doxorubicin and cyclophosphamide)
Trial: 29269583
Drug: Endobronchial coil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial coil treatment
Trial: 30150014
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg once daily administered orally)
Trial: 30150014
Drug: Vinorelbine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine and cisplatin chemotherapy (four cycles of vinorelbine [25 mg/m2 intravenously on days 1 and 8 of each 21-day cycle] plus cisplatin [75 mg/m2 intravenously on day 1 of each 21-day cycle])
Trial: 20170878
Drug: Enoxaparin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.5 mg/kg IV, 0.3 mg/kg SC)
Trial: 20170878
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (40 U/kg IV, 3,000 U maximum)
Trial: 15889218
Drug: Oral amoxicillin‐clavulanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin‐clavulanic acid 1.313 g 2 hours before operation (n = 208)
Trial: 15889218
Drug: Parenteral amoxicillin‐clavulanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral amoxicillin‐clavulanic acid 1.2 g intravenously 30 minutes before surgery (n = 200)
Trial: 10506395
Drug: Intensified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified therapy (pravastatin 20‐40 mg with addition of colestyramine and/or nicotinic acid)
Trial: 10506395
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (usual care antilipidemic therapy)
Trial: 8878253
Drug: Dexamethasone, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, 3 mg every eight hours for 48 hr
Trial: 30676234
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (blue/red light therapy patch)
Trial: 22466910
Drug: Everolimus with
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus with mycophenolate sodium (720 mg/day)
Trial: 22466910
Drug: Everolimus with
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus with low-exposure cyclosporine (3-8 ng/mL)
Trial: 11205935
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to perform five sequential sit-to-stand transfers in PAOD group (13.0 +/- 0.5 s)
Trial: 9204220
Drug: Daily self
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self monitoring of blood pressure
Trial: 9204220
Drug: No daily
RxNorm normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No daily self monitoring of blood pressure
Trial: 3296732
Drug: MTX, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX, 250 mg/m2 followed 1 h later by 5-FU, 600 mg/m2
Trial: 3296732
Drug: 5-FU followed
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU followed 1 h later by MTX in the same doses
Trial: 29324494
Drug: Glucose-Insulin-Potassium (GIK)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-Insulin-Potassium (GIK) - 20 IU of insulin, 10 mEq of potassium chloride in 50 mL of glucose 40%, administered over 60 minutes on anesthetic induction.
Trial: 29324494
Drug: Glucose-Insulin-Potassium (GIK)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-Insulin-Potassium (GIK)
Trial: 26585988
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg every 2 months (Q2M)
Trial: 23732968
Drug: Maintenance cognitive-behavioral
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance cognitive-behavioral therapy (CBT)
Trial: 19105803
Drug: Self-acquired stabilizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-acquired stabilizing ortheses (e.g., Aircast, Malleoloc)
Trial: 16880771
Drug: Pergolide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (0.1 mg)
Trial: 12717109
Drug: Flecainide acetate
RxNorm normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide acetate immediate-release (IR) 100 mg BID
Trial: 12717109
Drug: Flecainide acetate
RxNorm normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide acetate controlled-release (CR) 200 mg OD
Trial: 12717109
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of IR and CR formulations
Trial: 23073143
Drug: IR formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR formulation
Trial: 23073143
Drug: CR formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR formulation
Trial: 8864020
Drug: Catheter flush
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter flush with buffer solution through the sideport
Trial: 8864020
Drug: Washing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Washing the pumping unit with an alkaline solution after diverting pump flow at the sideport
Trial: 8864020
Drug: Procedures for
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Procedures for managing decreased insulin flow
Trial: 1832382
Drug: Isradipine (IS)
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine (IS) 2.5‐7.5 mg three times daily
Trial: 1832382
Drug: Nifedipine (NF)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NF) 10‐30 mg three times daily
Trial: 6344266
Drug: CMF +
RxNorm normalized name: Cyclophosphamide, Methotrexate, and Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF + immunotherapy
Trial: 22325903
Drug: Atacicept (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept (150 mg, subcutaneously, twice weekly for 4 weeks, then weekly) with MMF and tapered CS
Trial: 17909753
Drug: Naltrexone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (various doses)
Trial: 20561758
Drug: Naltrexone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone treatment condition (100mg vs. placebo)
Trial: 15777306
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hyperbaric bupivacaine at interspace L3‐4
Trial: 15777306
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bupivacaine through spinal catheter with EMG-guidance (Group CSA)
Trial: 15777306
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus of bupivacaine (15‐20 mg) at L3‐4 (Group Bolus)
Trial: 12572376
Drug: Shutianing Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shutianing Granule (STNG) 9 g, three times a day for 28 days
Trial: 12572376
Drug: Composite Yangjiao
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite Yangjiao capsule, 5 capsules each time, three times a day for 28 days
Trial: 12572376
Drug: Flunarizine hydrochloride
RxNorm normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine hydrochloride capsule, 5 mg, once a day for 28 days
Trial: 2944380
Drug: enprostil (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enprostil (35 micrograms twice daily)
Trial: 8574332
Drug: misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: misoprostol (200 micrograms four times daily)
Trial: 381599
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone (16 mg/day)
Trial: 381599
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (96 mg/day)
Trial: 381599
Drug: Dexamethasone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (both doses)
Trial: 26428286
Drug: Customized configuration
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized configuration for medication alert override reasons
Trial: 26428286
Drug: Non-customized configuration
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-customized configuration for medication alert override reasons
Trial: 23298374
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg/day for 1 week
Trial: 16836164
Drug: 0.3 mg/mL
RxNorm normalized name: menthol 0.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/mL rhPDGF‐BB + beta‐TCP
Trial: 16836164
Drug: rhPDGF‐BB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhPDGF‐BB treatment groups
Trial: 12776476
Drug: 10% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose injection
Trial: 12776476
Drug: 25% dextrose
RxNorm normalized name: Delflex with 4.25% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% dextrose injection
Trial: 12776476
Drug: 10% or
RxNorm normalized name: Xylocaine 10% Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% or 25% dextrose injection based on patient preference
Trial: 10877732
Drug: Hyperbaric bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine, 0.5%, 15 mg (3 ml) injected intrathecally
Trial: 10877732
Drug: Hyperbaric bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine, 0.5%, 15 mg (3 ml) injected intrathecally with torso elevated 30 degrees
Trial: 9165550
Drug: Morning dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dose of tacrolimus
Trial: 9165550
Drug: Evening dose
RxNorm normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dose of tacrolimus
Trial: 1375485
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus G‐CSF
Trial: 1375485
Drug: Peripheral blood
RxNorm normalized name: Peripheral blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood mononuclear cells harvested after chemotherapy plus G‐CSF
Trial: 3910524
Drug: Vancomycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (500 mg six hourly for seven days)
Trial: 3910524
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg six hourly for seven days)
Trial: 29703793
Drug: MET 1000
RxNorm normalized name: Fortamet 1000mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET 1000 mg BID
Trial: 29703793
Drug: COMBI (MET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMBI (MET 1000 mg BID + liraglutide 1.2 mg QD s.c.)
Trial: 23040114
Drug: Lower hemoglobin
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower hemoglobin levels (≤ 11 g/dL)
Trial: 23040114
Drug: Hemoglobin levels
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin levels >11-12 g/dL
Trial: 23040114
Drug: Hemoglobin levels
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin levels >12-13 g/dL
Trial: 23040114
Drug: Hemoglobin levels
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin levels >13-14 g/dL
Trial: 23040114
Drug: Hemoglobin levels
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin levels >14-15 g/dL
Trial: 23040114
Drug: Hemoglobin levels
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin levels >15 g/dL
Trial: 17583621
Drug: Iron-fortified toddler
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified toddler formula (500 mL/day)
Trial: 17583621
Drug: Unmodified cow's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmodified cow's milk (500 mL/day)
Trial: 12575622
Drug: Palivizumab (SYNAGIS)
RxNorm normalized name: palivizumab Injection [Synagis]
DrugBank: Palivizumab (DB00110)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Palivizumab (SYNAGIS) - 5 monthly injections
Trial: 9647273
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate powder at a dose of 16 mg/day administered by a metered dose inhaler (Group A)
Trial: 9647273
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate aqueous solution at a dose of 80 mg/day administered by a nebulizer (Group N)
Trial: 9647273
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate aqueous solution (80 mg/day) combined with salbutamol (3 mg/day) administered by a nebulizer (Group C)
Trial: 2480798
Drug: HPA-23 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HPA-23 treatment
Trial: 1103207
Drug: Haloperidol (0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (0.035 mg/kg)
Trial: 23291729
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose influenza vaccine (30 μg/strain)
Trial: 23291729
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose influenza vaccine (15 μg/strain)
Trial: 21885537
Drug: Manual lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual lymph drainage in addition to guidelines and exercise therapy
Trial: 21885537
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (guidelines and exercise therapy without manual lymph drainage)
Trial: 16675716
Drug: 1 g/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/m² of IV methotrexate over 24 hr (Group 1)
Trial: 16675716
Drug: 2 g/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/m² of IV methotrexate over 4 hr (Group 2)
Trial: 15723939
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of m‐THPC 6 days before direct endoscopic PDT with 80 to 100 J of light for adults and 60 to 80 J for children
Trial: 7701450
Drug: Salbutamol 2
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 2 mg (S2)
Trial: 7701450
Drug: Salbutamol 4
RxNorm normalized name: Salbutamol 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 4 mg (S4)
Trial: 7701450
Drug: Salbutamol 8
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 8 mg (S8)
Trial: 7701450
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg (PR)
Trial: 333188
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 300 mg every 6 hours for up to 5 days or until 1 day after chest tube removal
Trial: 31840263
Drug: Family-focused treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused treatment for childhood depression (FFT-CD)
Trial: 24690589
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg per day)
Trial: 16808682
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of approximately 20 mg of triamcinolone acetonide (TA)
Trial: 15046713
Drug: Novel agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel agents tested with chemotherapy
Trial: 15046713
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of previously studied chemotherapeutic agents
Trial: 2526101
Drug: Etodolac (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (600 mg daily)
Trial: 17113426
Drug: Diclofenac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (150 mg daily)
Trial: 2526101
Drug: Subjective drug
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective drug preference
Trial: 334083
Drug: Systemic cloxacillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic cloxacillin therapy
Trial: 28244897
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication (telmisartan)
Trial: 23721363
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (25 mg)
Trial: 23721363
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with valsartan (320 mg) and hydrochlorothiazide (25 mg)
Trial: 23721363
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with amlodipine (10 mg) and valsartan (320 mg)
Trial: 23721363
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with amlodipine (10 mg) and hydrochlorothiazide (25 mg)
Trial: 19786244
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of autogenous arteriovenous fistulae
Trial: 11583718
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (0.625 mg daily) for 3 months
Trial: 8215814
Drug: Imipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (mean maximum daily dose, 143 mg)
Trial: 8215814
Drug: Trazodone (255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (255 mg)
Trial: 8215814
Drug: Diazepam (26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (26 mg)
Trial: 8215814
Drug: Antidepressants (Imipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (Imipramine and Trazodone)
Trial: 3651278
Drug: Alcohol 0.2
RxNorm normalized name: benzyl alcohol 0.25 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol 0.2 g kg‐1
Trial: 3651278
Drug: Alcohol 0.4
RxNorm normalized name: isopropyl alcohol 0.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol 0.4 g kg‐1
Trial: 3651278
Drug: Alcohol 0.8
RxNorm normalized name: isopropyl alcohol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol 0.8 g kg‐1
Trial: 29069370
Drug: idd sequential
RxNorm normalized name: IDD-3
DrugBank: IDD-3 (DB05427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: idd sequential epirubicin, paclitaxel and cyclophosphamide (iddEPC) q2w
Trial: 27364568
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) given alongside measles-rubella and yellow fever vaccines
Trial: 27364568
Drug: Fractional intradermal
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional intradermal doses of IPV
Trial: 27364568
Drug: Measles-rubella and
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles-rubella and yellow fever vaccines co-administered with IPV
Trial: 3026106
Drug: Poliovirus vaccine
RxNorm normalized name: POLIOVIRUS VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poliovirus vaccine
Trial: 22250189
Drug: Topical carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical carmustine following intravenous O6-benzylguanine
Trial: 22250189
Drug: Topical carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical carmustine